Status:
COMPLETED
Efficacy of Glucagon-like Peptide-1 Receptor Agonists According to Type 2 Diabetes Subtypes
Lead Sponsor:
Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari
Conditions:
Diabetes Mellitus, Type 2
Eligibility:
All Genders
50+ years
Brief Summary
The goal of this observational retrospective study is to understand whether glucagon-like peptide-1 receptor agonists (GLP-1RA), which are a group of antidiabetes drugs, may act differently in differe...
Detailed Description
Patients with type 2 diabetes are all characterized by hyperglycemia, however their probability to develop micro- and micro-vascular complications. A classification of adult-onset diabetes in 5 subtyp...
Eligibility Criteria
Inclusion
- Italian patients with type 2 diabetes
- Onset of diabetes at ≥ 50 years
- Diagnosis of type 2 diabetes ≤ 5 years from enrollment
- BMI ≥ 25 kg/m2
- Patients receiving a GLP-1RA prescription for the first time with at least one follow-up visit at 6-12 months from first prescription
Exclusion
- Autoimmune diabetes, monogenic diabetes, secondary diabetes
- History of diabetic ketoacidosis
Key Trial Info
Start Date :
June 10 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 31 2023
Estimated Enrollment :
130 Patients enrolled
Trial Details
Trial ID
NCT06120556
Start Date
June 10 2023
End Date
October 31 2023
Last Update
January 30 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Azienda Ospedaliero-Universitaria Policlinico Bari
Bari, Italy, 70124